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Background: Cerebrolysin is a neuropeptide preparation with neuroprotective and neurorestorative effects.
Combining Cerebrolysin treatment with a standardized rehabilitation program may have a potential synergistic
effect in the subacute stage of stroke. This study aims to evaluate whether Cerebrolysin provides additional motor
recovery on top of rehabilitation therapy in the subacute stroke patients with moderate to severe motor
impairment.
Methods: This phase IV trial was designed as a prospective, multicenter, randomized, double-blind, placebo-controlled,
parallel-group study. A total of 70 patients (Cerebrolysin n = 35, placebo n = 35) with moderate to severe
motor function impairment were included within 7 days after stroke onset and were randomized to receive a
21-day treatment course of either Cerebrolysin or placebo, given in addition to standardized rehabilitation
therapy. Assessments were performed at baseline, immediately after treatment as well as 2 and 3 months
after stroke onset. The plasticity of motor system was assessed by diffusion tensor imaging and with resting
state functional magnetic resonance imaging.
Results: Both groups demonstrated significant improvement in motor function (p < 0.05); however, no significant
difference was found between the two groups. In the stroke patients with severe motor impairment, the Cerebrolysin
group exhibited significantly more improvement in motor function compared with the placebo group (p < 0.05).
Effects of Cerebrolysin were demonstrated as restricted increments of corticospinal diffusivity and as recovery of the
sensorimotor connectivity.
Conclusion: The combination of standard rehabilitation therapy with Cerebrolysin treatment in the subacute stroke
has shown additional benefit on motor recovery and plastic changes of the corticospinal tract in patients with severe
motor impairment.
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Motor impairment is a major cause of disability in activ-
ities of daily living in stroke survivors [1]. Many rehabili-
tation strategies attempt to enhance motor recovery in
stroke patients, however, the effects are limited espe-
cially for patients with severe motor impairment [2]. In-
nate physiological and anatomical plasticity contributes
to the substantial gains achieved in motor function after
stroke, and the combination of task-specific training and
general aerobic exercise is still the gold standard for
post-stroke rehabilitation [3]. In particular, the subacute
stage after stroke is the critical period during which the
brain is most receptive to modification by rehabilitative
experiences [4–6].
Cerebrolysin (EVER Neuro Pharma GmbH, Austria)
is a neuropeptide preparation of low molecular-weight
peptides and free amino acids with neuroprotective
and neurorestorative effects [7]. Recently published
trials have shown a trend for favorable outcome of
Cerebrolyin in acute stroke patients [8, 9]. Specifically,
Cerebrolysin has been shown to enhance neurogenesis in
the dentate gyrus of the hippocampus [10], which indi-
cates that the compound is capable of stimulating the
restorative capacity of the brain after injury. Upregula-
tion of neurogenesis occurs naturally, and plays an im-
portant role in the recovery of neurological function
after an ischemic stroke [7]. Therefore, Cerebrolysin
may possess the potential to accelerate this process in
stroke. Cerebrolysin, furthermore, demonstrated neuro-
tropic effects by imitating natural neurotrophic factors, in
addition to the previously mentioned effects [11]. Consid-
ering that natural adaptations to injury occur rapidly and
on a wide scale in the subacute stage of stroke [4–6], the
subacute stage would constitute the most appropriate time
window for enhancing neurotrophic effects of the targeted
agent, such as Cerebrolysin. However, no clinical trials
have been performed so far in the subacute stage of stroke
investigating a potential synergistic effect of combining
Cerebrolysin treatment with a standardized rehabilitation
program.
The purpose of this study was to evaluate the efficacy
of Cerebrolysin in terms of promoting additional motor
recovery on top of a rehabilitation therapy during the
subacute phase of stroke in patients with moderate to
severe motor impairment. Evidence for the effects of
Cerebrolysin on neuroplasticity has been investigated
using functional neuroimaging.
Methods
Participants
Patients were included in the study within the first 7 days
after stroke if they suffered from a first cortical, subcor-
tical, or cortical-subcortical unilateral infarction con-
firmed by brain CT or MRI, with moderate to severemotor function involvement (total score of Fugl-Meyer
assessment (FMA) 0–84) [12], had an inpatient status
and were at the age between 18 and 80 years.
Exclusion criteria were progressive or unstable
stroke, pre-existing and active major neurological dis-
ease or major psychiatric disease, a history of signifi-
cant alcohol or drug abuse within the last 3 years,
advanced liver, kidney, cardiac or pulmonary disease, a ter-
minal medical diagnosis consistent with survival <1 year,
substantial decrease in alertness at the time of
randomization (score of ≥2 in National Institutes of
Health Stroke Scale (NIHSS) item 1a), pregnancy or
lactation, any condition contraindicated to Cerebroly-
sin including allergy to Cerebrolysin, participation in
another stroke study, abnormal lab data or cardiopul-
monary deficits interfering in physiotherapy, and a
history of porcine brain peptide administration. Writ-
ten informed consent was obtained from all subjects
prior to inclusion in the study and the study protocol
was approved by the Institutional Review Board (IRB)
of each participating center (SMC IRB (2010-09-084,
the leading ethics committee), Severance Hospital IRB
(4-2012-0308), PNUYH IRB (02-2010-057), and CUH
IRB (2010-10-154)).
Experimental design
This IV trial was designed as a prospective, multicenter,
randomized, double-blind, placebo-controlled, parallel-
group study. The screening visit was performed within
7 days after stroke; demographic data, medical history,
and data on physical examination and laboratory tests
were documented. Enrolled patients were randomized to
receive a 21-day treatment course (Days 8–28) of either
Cerebrolysin or placebo, given as add-on to standardized
rehabilitation therapy. Cerebrolysin was administered
once daily at a dosage of 30 mL diluted with saline (total
infusion solution 100 mL) by intravenous infusion over a
time period of 30 min. Patients of the placebo group re-
ceived 100 mL of saline instead. In addition, all patients
received a standardized rehabilitation program consist-
ing of 2 h of physical therapy and 1 h of occupational
therapy daily on workdays (Monday to Friday). All
patients in this study underwent the passive range of
motion exercise in the patient’s room without com-
prehensive rehabilitation therapy before enrollment.
After baseline assessment (Day 8; T0) efficacy and
safety have been assessed immediately after treatment
(Day 29; T1; study endpoint) as well as two (Day 60; T2)
and three (Day 90; T3) months after stroke onset. The
changes in neuroplasticity of the motor network were
assessed by diffusion tensor imaging (DTI) and resting
state functional magnetic resonance imaging (rsfMRI) at
T0, T1, and T3. The study duration for each patient was
90 days.
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Stroke severity at T0 was recorded using the NIHSS [13]
in all enrolled patients. In addition, structural MRI data
at T0 were used to assess initial lesion volumes of
patients. The data were transformed to the same coord-
inate frame as the template brain, conforming to the
Montreal Neurological Institute (MNI) space using the
New Segment routine in Statistical Parametric Mapping
(SPM)(http://www.fil.ion.ucl.ac.uk/spm/). Each patient’s
lesion was manually delineated on the normalized struc-
tural image and then saved as a binary mask image. The
number of voxels that composed the lesion mask was
counted, and the volume of the lesion was measured by
multiplying the voxel number by the voxel size.
Motor function assessment
For motor function assessment, FMA was evaluated at
baseline (T0), immediately after treatment (T1), two
(T2) and three (T3) months after stroke onset. FMA
scores were recorded separately for the upper limb
(FMA-UL), lower limb (FMA-LL), and the total score
(FMA-T). FMA has well-established reliability and valid-
ity as an indicator of motor impairment severity across
different stroke recovery time points [14].
Motor network plasticity assessment
The assessment of motor network plasticity was based
on imaging data obtained from DTI and rsfMRI.
DTI data were collected using a 3 Tesla MR scanner.
For every patient 46 whole brain images were acquired
using a single-shot diffusion-weighted echo planar im-
aging sequence. The data set comprised 45 images with
high diffusion weighting (b value = 1000 s/mm2) applied
along 44 diffusion directions and one image with no dif-
fusion weighting. Each image included 60 2.25-mm thick
axial slices of 1.96 mm × 1.96 mm in-plane resolution.
The data were preprocessed using the diffusion toolbox
(FDT) included in the Functional Magnetic Resonance
Imaging of the Brain’s (FMRIB) Software library (FSL)
(http://fsl.fmrib.ox.ac.uk/fsl/) [15]. A diffusion tensor
was modeled for each voxel, and fractional anisotropy
(FA), axial diffusivity (AD), and radial diffusivity (RD)
were computed from the diffusion tensor [16]. The maps
of the DTI parameters in individual patients’ native
space were transformed to the MNI space. As an alter-
native approach to tracking the corticospinal tract (CST)
of every patient, a template CST acquired from healthy
controls was used as a standardized approach to meas-
ure corticospinal integrity when using DTI data [17]. For
generating the template CST, probabilistic tractography
of the CST was performed for age-matched 23 healthy
controls (mean age 53.5 ± 4.8 years). Tract-wise DTI pa-
rameters were calculated as the average of values read
over the whole extent of the template CST, rather thanover some regions of interest covering the partial extent
of the template CST. For individual patients, CST-wise
FA, AD, and RD were computed for the CST in the ipsi-
lesional hemisphere (FAipsi, ADipsi, and RDipsi).
Resting state functional magnetic resonance imaging
(rsfMRI) data were collected using the same scanner
as for DTI data. For every patient 100 whole brain
images were acquired using a gradient echo planar
imaging sequence (repetition time = 3000 ms, echo
time = 35 ms). Each image included 35 4.00-mm thick
axial slices of 1.72 mm × 1.72 mm in-plane resolution.
The data were preprocessed using the routines in SPM
(http://www.fil.ion.ucl.ac.uk/spm/) and Data Processing
Assistant for Resting-State fMRI DPARSF (http://
rfmri.org/DPARSF). Preprocessing steps included spatial
realignment to the mean image, normalization to the
same coordinate frame as the template brain con-
forming to the MNI space, spatial smoothing with a
Gaussian kernel of 4 mm Full Width at Half Maximum
(FWHM), removal of the systematic drift or trend, regres-
sing out nuisance covariates such as the cerebrospinal
fluid and white matter signals, and band-pass filtering at
0.01 to 0.08 Hz.
To estimate a sensorimotor network based on resting
state functional connectivity, the representative time
course from the primary motor cortex (M1) in the ipsile-
sional hemisphere served as a reference in determining
correlation coefficients with all other time courses from
the brain. The sensorimotor network for each group was
displayed by thresholding a statistical parametric map of
t-values calculated from a one sample t-test of individual
patients’ sensorimotor networks, at an extent threshold
of a p-value of 0.05 family-wise error corrected for
multiple comparisons with a cluster-forming threshold
of a p-value of 0.001. Furthermore, we computed a
lateralization index (LI) between bilateral primary sen-
sorimotor cortices (SM1s) by using the map of correl-
ation coefficients to quantify a degree of symmetry of
the sensorimotor network. For the voxels having
values over the 95th percentile in the map, the LI
was defined as the difference in the ratio of the vox-
els between ipsilesional and contralesional SM1s, such
that LIs close to 0 referred to a symmetry in func-
tional connectivity as exhibited in healthy individuals’
sensorimotor network.
Safety analyses
A complete medical history and physical examination
including vital signs were performed at screening. La-
boratory data (hematology, blood chemistry, urinalysis)
were assessed at all study visits from baseline (T0) to
Day 90 (T3). All adverse events after giving informed
consent have been documented and evaluated in terms
of severity and causality.
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A sample size was determined a priori, which assumed a
2-tailed independent t-test with α equal to 0.05 and
power at 80 %. The sample size was determined to be
sufficient to detect a difference (δ) of 0.20 on the im-
provement of FMA-T from T0 to T1 as a primary
outcome measure, with respective standard deviations
of 0.27, as calculated from results of a similar previ-
ous study performed by our group [18]. Using the
Lehr’s formula (16/(δ/σ)) [19] and a 15 % drop-out
rate, it was calculated that 70 subjects in all would be
needed.
In this study, the primary analysis was based on the
intention to treat (ITT) population using the last obser-
vation carried forward method (LOCF), which included
all randomized patients who received a least one dose of
study medication and had a baseline and at least one
post-baseline assessment of the primary endpoint (full
analysis set). LOCF is characterized by individual miss-
ing values being replaced by the last observed value of
that variable. The safety population included all patients
who received at least one dose of study medication. Pre-
planned stratified analyses for severe motor impairment
at baseline (FMA-T <50) and moderate motor impair-
ment at baseline (50≤ FMA-T ≤84) were performed in
addition [20].Fig. 1 Enrollment and disposition of all patients participating in the clinicaSPSS version 21.0 (SPSS, Chicago, IL, USA) was used
for the statistical analyses. The difference in the continu-
ous outcome between Cerebrolysin and placebo group
was assessed using independent t-test. Frequency differ-
ences were tested using χ2-test or Fisher’s exact test. To
test the effects of Cerebrolysin across all time points we
used the repeated measures ANOVA with time as the
within-patient factor and group (Cerebrolysin vs. pla-
cebo) as the between-patient factor for the parametric
data with normal distribution. To correct for multiple
comparisons made, a Bonferroni correction was used. A
large F-value in the repeated measures ANOVA yields a
correspondingly small p-value. The effect on FMA at T3
and its improvement from baseline was analyzed by a
simple regression model with one independent variable
by group. This analysis was performed to evaluate the
pattern of motor function improvement at T3 in each
group. P-values less than 0.05 were considered statisti-
cally significant.
Results
A total of 70 patients have been enrolled in this study
(Fig. 1) from four study centers. All patients received
at least one dosage of study medication (Cerebrolysin
n = 35, placebo n = 35), thus representing the safety
analysis set. A total of nine patients have discontinuedl study. ITT, intention-to-treat
Table 1 Comparison of baseline characteristics (ITT analysis set)
Demographic parameter Cerebrolysin
(n = 34)
Placebo
(n = 32)
Male sex: N (%) 29 (82.9) 24 (72.7)
Mean age: years (SD) 64.7 (10.1) 63.0 (10.6)
Mean weight: kg (SD) 65.4 (11.3) 66.7 (12.7)
Mean height: cm (SD) 165.7 (8.6) 165.7 (9.6)
Prevalence of risk factors: N (%)
Hypertension 20 (57.1) 11 (33.3)
Hyperlipidemia 1 (2.9) 4 (12.1)
Diabetes mellitus 10 (28.6) 9 (27.3)
Arrhythmia 3 (8.6) 0 (0.0)
Coronary artery disease 3 (8.6) 4 (12.1)
Stroke side: N (%), Rt : Lt 14 (41.2) :
20 (58.8)
20 (62.5) :
12 (37.5)
Stroke etiology: N (%)
Large artery atherosclerosis 13 (38.2) 11 (34.4)
Small vessel occlusion 10 (29.4) 14 (43.8)
Cardioembolism 7 (20.6) 4 (12.5)
Other determined 1 (2.9) 1 (3.1)
Undetermined ischemic stroke 3 (8.8) 2 (6.3)
Stroke lesion: N, cortical : subcortical :
cortical-subcortical)
7: 6 : 21 8: 3 : 22
Stroke lesion characteristics
Cortex 7 8
Cortex/BG/IC 3 0
Cortex/BG/IC/Corona radiata 3 1
Cortex/Corona radiata 0 2
BG/IC 9 14
BG/IC/Corona radiata 3 3
Corona radiata 8 3
Thalamus 1 2
Initial stroke treatment: N
Intravenous thrombolysis 5 3
Intraarterial thrombolysis 1 2
Intraarterial thrombectomy 2 2
Baseline stroke severity: Mean (SD)
NIHSS 8.4 (5.8) 7.0 (4.9)
Lesion volumes: cm3 15.560 (27.023) 19.253 (18.846)
Total FMA 42.0 (24.2) 42.2 (28.5)
Upper limb of FMA 24.6 (18.8) 26.7 (20.7)
Lower limb of FMA 17.4 (9.5) 15.5 (10.0)
ITT intention-to-treat, BG basal ganglia, IC internal capsule, NIHSS National
Institutes of Health Stroke Scale, FMA Fugl-Meyer assessment
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(hemorrhagic transformation; placebo n = 1), by withdraw-
ing their consent (Cerebrolysin n = 2, placebo n = 5) or be-
cause of protocol violation (Cerebrolysin n = 1). A total of
four patients (Cerebrolysin n = 1, placebo n = 3) had no
post-baseline data and thus was excluded from the ITT
analysis set (Cerebrolysin n = 34, placebo n = 32). The
mean age of the patients was 64.2 ± 11.5 years, the
proportion of males was 77.9 %, and the NIHSS mean
was 7.6 ± 5.4. There were no relevant group differ-
ences from the ITT analysis set at baseline in general
characteristics, stroke characteristics, or initial thromboly-
sis therapy (Table 1). There tended to be a higher propor-
tion of patients with hypertension and arrhythmia in the
Cerebrolysin group and relatively higher proportion of pa-
tients with hyperlipidemia, coronary artery disease and
small vessel occlusion in the placebo group, but these dif-
ferences are not statistically significant. There was no sig-
nificant difference in NIHSS, lesion volume, and motor
function measured by FMA at T0 between the two
groups. In addition, there was no significant difference in
presence of neglect in NIHSS at T0 between the two
groups (Cerebrolysin n = 6, placebo n = 4). In subgroup
analysis with severe motor impairment and moderate
motor impairment at baseline, there was no signifi-
cant difference in baseline characteristics between the
Cerebrolysin and the placebo groups.
Motor function assessment
In the ITT-LOCF analyses set both groups improved sig-
nificantly over time in the FMA. However, repeated
measures ANOVA showed no significant interaction ef-
fect between time and type of intervention as measured
by FMA scores (FMA-T, FMA-UL, and FMA-LL). There
were no significant differences in the improvement of
FMA scores (FMA-T, FMA-UL, and FMA-LL) at T3
between the groups. The improvement of FMA-T and
FMA-UL tended to be higher in the Cerebrolysin group
than in the placebo group, but without statistical signifi-
cance (Fig. 2).
In the ITT-LOCF subgroup analysis of patients with
severe motor impairment on T0 (n = 37; Cerebrolysin
n = 20, placebo n = 17; FMA-T at T0 <50), repeated
measures ANOVA showed a significant interaction ef-
fect between time and type of intervention as mea-
sured by FMA-T (F3,102 = 4.596, p < 0.05)(Fig. 2a-1 right
panel) and FMA-UL (F3,102 = 3.605, p < 0.05)(Fig. 2b-1
right panel). In addition, there was a significant group
difference in the FMA-T (Fig. 2a-2 right panel) and
FMA-UL (Fig. 2b-2 right panel) at T2 and T3. The
simple regression analysis showed a relationship be-
tween FMA-T at T0 and T3 in both groups (Cerebrolysin
r2 = 0.7230, p < 0.001, Fig. 2d-1 and placebo r2 = 0.9018,
p < 0.001, Fig. 2d-2). However, the improvement ofFMA-T at T3 showed no relationship with baseline scores
(T0) in the Cerebrolysin group (r2 = 0.0086, p = 0.6137;
Fig. 2d-1), whereas the placebo group demonstrated a
Fig. 2 Changes in the Fugl-Meyer assessment (FMA) for Cerebrolysin (30 ml/day) and placebo at baseline (Day 8, T0), immediately after treatment
(Day 29, T1) as well as two (Day 60, T2) and three (Day 90, T3) months after stroke onset. Analysis was based on the intention-to-treat (ITT) population
using the last observation carried forward (LOCF) approach for missing data and the subgroup of patients with severe motor impairment (ITT-LOCF,
FMA <50). The ITT-LOCF population included a total of 66 patients (Cerebrolysin n = 34, placebo n = 32), the subgroup a total of 37 patients
(Cerebrolysin n = 20, placebo n = 17). Time courses (1) and improvements from baseline (2) are given for the total score of FMA (a), the
upper limb subscore (b) and the lower limb subscore (c) for the total population (left panel) and the severe subgroup (right panel). d The
simple regression analysis showed a significant relationship between FMA-T at T0 and T3 in both groups (Red dots and broken lines, Cerebrolysin group,
d-1; placebo group, d-2). The improvement of FMA-T at T3 showed no relationship with baseline T0 scores in the Cerebrolysin group (d-1) (Blue dots),
whereas the placebo group demonstrated a tendency of relationship between these two measures (d-2) (Blue dots and line). *p < 0.05 between time
points in each group; **p < 0.05 between both groups; ***p < 0.05 between groups over time (repeated measures ANOVA)
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(r2 = 0.1184, p = 0.0676, Fig. 2d-2).
In the ITT-LOCF subgroup analysis of patients with
moderate motor impairment on T0 (n = 29; Cerebrolysin
n = 14, placebo n = 15; 50≤ FMA-T at T0 ≤84), repeated
measures ANOVA showed no significant interaction ef-
fect between time and type of intervention as measured
by FMA scores (FMA-T, FMA-UL, and FMA-LL).
Motor network plasticity assessment
In DTI analysis of the CST based on the ITT-LOCF
subgroup analysis of patients with severe motor im-
pairment on T0, repeated measures ANOVA showed
significant interactions between time and type of
intervention for ADipsi (F2,59 = 2.831, p < 0.05, Fig. 3b-1)
and RDipsi (F2,59 = 3.490, p < 0.05, Fig. 3c-1). Moreover,Fig. 3 Changes in the diffusion tensor imaging (DTI) for Cerebrolysin (30 m
(Day 29, T1) and three (Day 90, T3) months after stroke onset. Analysis was ba
carried forward (LOCF) approach for missing data in the subgroup of patients
from baseline (2) are given for the fractional anisotropy (FA; a), the axial diffus
points in each group; **p < 0.05 between both groups; ***p < 0.05 between gthere were significant differences between the two groups
in the changes of ADipsi and RDipsi at T3 (p < 0.05)
(Fig. 3b-2, C-2). For FAipsi, however, repeated measures
ANOVA showed no significant interaction between time
and type of intervention (Fig. 3a-1, A-2). In the ITT-
LOCF subgroup analysis of patients with moderate motor
impairment on T0, repeated measures ANOVA showed
no significant interaction effect between time and
type of intervention as measured by DTI (FAipsi,
ADipsi and RDipsi).
Among the ITT-LOCF subgroup analysis of patients
with severe motor impairment on T0, rsfMRI data
were analyzed from 29 patients (Cerebrolysin n = 13,
placebo n = 16). Changes in the sensorimotor network
across time showed increased symmetric functional
connectivity between the bilateral primary sensori-motorl/day) and placebo at baseline (Day 8, T0), immediately after treatment
sed on the intention-to-treat (ITT) population using the last observation
with severe motor impairment (FMA <50). Time courses (1) and changes
ivity (AD; b), and the radial diffusivity (RD; c). *p < 0.05 between time
roups over time (repeated measures ANOVA)
Chang et al. BMC Neurology  (2016) 16:31 Page 8 of 11cortices (SM1s) specifically in the Cerebrolysin group
(Fig. 4a-1, a-2). Indeed, although repeated measures
ANOVA showed no significant interaction between
time and type of intervention in the analysis of the
lateralization index (LI) between bilateral SM1s,
(Fig. 4b-2), only Cerebrolysin showed a significant differ-
ence in the change of the LI at T1 and T3 (Fig. 4b-1).
Safety analyses
Of all patients treated a total of 94.3 % received 21 infu-
sions (Cerebrolysin 97.1 %, placebo 91.4 %). In each
study group one patient suffered from a serious adverse
event (SAE), none of both SAEs was rated as related toFig. 4 Resting state of the sensorimotor network as shown by the resting
placebo (a2) in the affected (AH) and unaffected (UH) hemispheres at base
(Day 90, T3) months after stroke onset. Analysis was based on the intention
(LOCF) approach for missing data in the subgroup of patients with severe
placebo n = 16). Time course (b1) and changes from baseline (b2) are give
each groupstudy medication. The SAE in the Cerebrolysin group
was described as cholecystitis with gallstone, which re-
solved during the study period. The SAE in the placebo
group was a hemorrhagic transformation of the cerebral
infarction, the patient discontinued study participation
due to this event. None of the patients died during the
study. Vital signs and laboratory values were similar
between treatment groups and did not show clinically
relevant changes during the course of the study.
Discussion
The goal of this study was to investigate whether a
3 weeks treatment with Cerebrolysin in the subacutestate functional MRI (rsfMRI) for Cerebrolysin (30 ml/day; a1) and
line (Day 8, T0), immediately after treatment (Day 29, T1) and three
-to-treat (ITT) population using the last observation carried forward
motor impairment (FMA <50) from 29 patients (Cerebrolysin n = 13,
n for the lateralization index. *p < 0.05 between time points in
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tion therapy provides additional benefit on motor
recovery in patients with moderate to severe motor
impairment. The results of this study revealed that
Cerebrolysin treatment for 3 weeks in the subacute
phase of stroke, in addition to rehabilitation therapy,
tended to show better improvement of motor function
at 3 months after stroke onset than was seen in the pla-
cebo group, but without statistical significance. However,
in patients with severe motor involvement at 7 days after
stroke onset, Cerebrolysin as an additional treatment
with a standardized rehabilitation showed significant
better improvement of motor function at 3 months after
stroke onset. Also, Cerebrolysin treatment for 3 weeks
during the subacute phase of stroke showed no serious
adverse effects. The combination of standard rehabilita-
tion therapy with Cerebrolysin treatment in the subacute
stroke has shown additional benefit on motor recovery
in patients with severe motor impairment.
The optimal timing for rehabilitation is still under dis-
cussion but there is evidence that an earlier start of re-
habilitation might be more effective [21]. In fact, the
therapeutic time window for functional recovery seems
to be relatively broad from days to weeks [22]. Func-
tional recovery refers to enhanced sensory and motor
performance after stroke and might also include a vary-
ing degree of behavioral compensation [21]. However,
pure recovery is based on the neuroplasticity and takes
advantage of the diffuse and redundant connectivity
existing in the brain and the remapping between related
cortical regions in order to form new structural and
functional circuits [21]. Animal studies have shown simi-
larities in plasticity-relevant gene expression and transla-
tion between early brain development and the semi-
acute phase after stroke [21]. These genes and proteins
are important for neuronal growth, synaptogenesis and
the proliferation of dendritic spines. Previous in vivo and
in vitro studies have shown similar effects on neurons by
Cerebrolysin [23–29]. In animal stroke studies [28, 30]
rehabilitation of motor-sensory function was signifi-
cantly increased when Cerebrolysin administration was
initiated within 48 h after stroke, however, in humans
the time window for recovery is expected to be longer or
even never really closing but plastic processes diminish
and slow with time [21].
This study could not achieve the primary objective to
evaluate the efficacy of Cerebrolysin for motor recovery
measured the improvement of FMA-T from baseline to
immediate after treatment in patients with moderate to
severe motor impairment. However, a combination of a
standardized rehabilitation program with Cerebrolysin
treatment was more effective on the improvement of se-
vere motor deficits at 3 months after stroke onset as
compared to a combination with placebo. In addition,regression analysis has shown that the magnitude of im-
provement in motor functions by Cerebrolysin was inde-
pendent of baseline severity, which was reflected by a
faster and more pronounced motor improvement in pa-
tients with more severe motor impairment at baseline as
compared to placebo. This improvement might be con-
sidered as enhancement of motor control function
mainly in the upper extremities rather than in the lower
extremities as indicated by the separate analyses of
upper and lower extremities. No significant difference in
the improvement of motor function at immediately after
treatment may be due to relative small number of pa-
tients with severe motor involvement. This constitutes
one of the limitations of the present study. Further stud-
ies with a larger sample size will be needed to elucidate
this issue. A reason for failure of the primary objective
might be the reported the possible ceiling effect on hand
and lower extremity items [31]. Another reason might
be therapeutic potentials of stroke rehabilitation. The
additional effect of Cerebrolysin could be hidden due to
the conventional rehabilitation strategies in the subacute
stroke patients with moderate motor impairment. On
the other hand, the additional effect of Cerebrolysin
treatment in the subacute stroke stage could have im-
portant implications for stroke rehabilitation, because
the conventional rehabilitation strategies are somewhat
limited in their improvement of motor function in stroke
patients with severe motor involvement [2].
In subgroup of patients with severe motor impairment
at baseline, we additionally investigated the effect of
Cerebrolysin on motor network plasticity with DTI and
rsfMRI, which has been done for the very first time in a
Cerebrolysin study. CST-wise DTI analysis has shown
significant interactions for both RD and AD between
intervention types and time in such a way that increases
in the diffusivity across time were less steep or restricted
for the Cerebrolysin group. RD was shown to increase
after injury reflecting demyelination [32, 33] and thus, a
restriction of RD increments for the Cerebrolysin group
may suggest that Cerebrolysin plays a role in the protec-
tion against demyelination of the CST during the sub-
acute phase of stroke. On the other hand, a decrease in
AD may indicate axonal damage in the acute phase after
injury, whereas an elevation of AD may occur due to de-
generative processes in the chronic phase [33]. Interpret-
ation by connecting directional diffusivities to discrete
pathological processes is still controversial, but steeper
increases in AD as seen in the placebo group might
reflect a composite of degeneration and subsequent
structural compensation that does not necessarily yield
functionally meaningful connections [34]. In addition,
although no interaction between intervention types and
time was shown for FA, it is notable that FA started to
increase after T1 in the Cerebrolysin group, whereas it
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This may reflect recovery of corticospinal integrity pro-
moted by the pharmacological action of Cerebrolysin.
While CST-wise DTI parameters exhibit changes in the
motor-related white matter, the LI between bilateral
SM1s in the resting state sensorimotor network shows
changes in the motor-related cortical grey matter [35].
In the Cerebrolysin group symmetric functional con-
nectivity was more pronounced indicating a better re-
covery of motor cortical function.
This study possesses some limitations. Even though the
baseline motor function is the most important prognostic
factor, there are numerous other factors in motor recovery
in stroke patients, such as cognitive function, aphasia, co-
morbid medical conditions, stroke-related complications,
socioeconomic status, and extent of family and social sup-
port [2, 36–39]. In this study, a complete assessment at
baseline could not be performed for all potential prognos-
tic factors for motor recovery in stroke patients. The rela-
tively small number of patients enrolled in this study
could not allow multivariate models to adjust for more
confounding variables. Therefore, further study with a lar-
ger number of participants and long-term follow-up
would be necessary to better evaluate the effect of Cere-
brolysin in combination with rehabilitation on recovery in
subacute stroke patients. There was no significant differ-
ence in intensity and duration of rehabilitation therapy
after treatment (T1) between the two groups. However,
participants could not be regulated for rehabilitation ther-
apy from after treatment (T1) to 3 months after stroke on-
set (T3), although any other neuroprotective or nootropic
drug was not allowed until 3 months after stroke onset.
Stroke severity and age of stroke patients in this study
were relatively low compared with other stroke trials.
These might be due to many strict exclusion criteria on
the screening visit within 7 days after stroke. For the
motor network plasticity assessment in this study, we used
imaging data obtained from DTI and rsfMRI that have
been successfully applied in patients with acute and
chronic stroke to evaluate motor network [40, 41].
However, rsfMRI in stroke patients has certain limitations
as highly susceptible to motion-related artifacts because
patients tend to move more than controls [40]. Due to
these limitations, we could not analyze the rsfMRI data of
some participants. Especially, the number of patients who
provided analyzable rsfMRI data set for three time points
were limited in patients with moderate motor impairment;
ten in the Cerebrolysin group and only three in the
placebo group. Since these numbers were too small to
get a reliable group-level analysis, we did not address
group results for patients with moderate motor impair-
ment. Therefore, additional study will be needed to eluci-
date these issues. In spite of favorable outcomes of
Cerebrolysin in acute stroke patients [8], a recent review[42] did not demonstrate clinical benefits of Cerebrolysin
for treating acute ischemic stroke, and recommended
that further well-designed randomized controlled tri-
als would be required to obtain a better understand-
ing of the potential value or risks of Cerebrolysin in
acute ischemic stroke.
Conclusions
This study has shown that Cerebrolysin treatment over
3 weeks in combination with rehabilitation therapy in the
subacute phase of stroke is safe and provides a beneficial
effect on motor recovery in patients with severe motor
impairment. Furthermore, for the very first time neuroim-
aging data have shown that treatment with Cerebrolysin
had a beneficial influence on both, motor-related grey and
white matter. Further studies also with a larger sample size
will be needed to clarify the impact and the appropriate
time window for Cerebrolysin treatment in order to
optimize motor recovery after ischemic stroke by enhan-
cing motor network plasticity. Also, there were no safety
concerns with Cerebrolysin. From this study, Cerebrolysin
treatment as add-on to a rehabilitation program might be
considered as a pharmacologic approach for motor
recovery in ischemic stroke patients with severe motor
involvement in the subacute stage.
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